Press "Enter" to skip to content

How we can outsmart cancer byte by byte | Dr. Sunil Verma | TEDxCalgary


[Music]
cancer touches us all it’s a disease
that is meaningful yet scary is a
disease that causes significant
morbidity and mortality but we’re making
progress
today I’ll share with you how we
understand cancer much better now than
ever before I’ll share with you how our
treatments are evolving much better now
than ever before I’ll share with you how
we can use our own body to fight cancer
cells and then I’ll share with you the
challenge that is front of us and that
challenge is how do we outsmart chat on
cancer how do we defeat this disease and
I think the answer may lie in data let
me start off by talking a little bit
about the burden of cancer in 2015 there
were 17 million cancer diagnoses 17
million around the globe there were
nearly 8 million patients who died of
this disease in 2015 that was 30% more
than the rates that we saw in 2005 and
if we take a look at 2030
the next 15 years those rates are going
to continue to increase but roughly
double what we’re seeing right now we’re
going to see close to 13 million
patients will die of this disease and
close to 21 million and the reason is
aging population population growth and
some environmental factors and if you
take a look at these numbers they are
incredibly alarming it’s even more
alarming when we realize that 40 percent
of the cancer diagnoses are happening in
low and middle income countries but
nearly 70 percent of cancer deaths
happen in low and middle-income
countries so the cancer that we see
there is late advanced age of
presentation because of diagnostic
considerations are not there the
treatment may not be there so the burden
of cancer is being felt globally but
even more
and middle-income countries the key
thing of course is that we can prevent
cancer about 30 to 40% of cancers can be
prevented if we listen to these five
factors we exercise we eat healthy we
watch our weight we drink alcohol in
moderation no don’t drink and we don’t
smoke if you do those five things that n
decreases the risk of getting cancer by
about 30 to 40 percent still there’s
about a billion people in the world who
smoke what I want to focus on today is
the treatment I’m going to focus on how
do we understand this disease and how do
we develop the right treatment for the
right patient at the right time and in
order for us to be able to do that we
have to understand what is cancer so
cancer arises from a normal cell our DNA
the building units that drive our living
cells they get altered and our
alteration leads to a change in behavior
and that change in behavior is how
cancer cells are different than normal
cells
how are they different they’re more
likely to grow uncontrollably
there’s no sustainment in that growth
they just continue to grow they are more
likely to resist cell death that is
normal process in our own body where
their cell turnover but they don’t die
they’re more likely to invade and
metastasize and go to other parts of the
body which the normal cells are not able
to do they’re able to escape our own
immune system and they can hide away
from our own immune system they’re able
to create their own infrastructure the
create their own blood supply bringing
their own nutrients so they continue to
grow and they’re also able to mutate and
you would think why would cancer cells
want to mutate well they want to mutate
so that they can learn how to escape our
treatments these are incredibly smart
smart cells which have these superpowers
that we can now understand better and
maybe use some of those powers as
Achilles heel as we develop our
treatments so what ends in our arsenal
as we take a look at how we best help
answer patient we have surgery which is
very good at removing that cancers that
we can see we have radiation treatment
which is using x-ray beams to be able to
focus directly at the cancer cell and
target these cancer cells and we have
chemotherapy which works really well
against rapidly dividing cells such as
cancer cells but unfortunately comes
with significant toxicity as there’s a
lot of collateral damage that will
happen as a result of chemotherapy all
the mainstays of treatment now but
things have changed and things started
to change about two decades ago as we
started to understand what is it that’s
driving cancer and that came with an era
of targeted therapy we started to
understand that these are receptors on
these cancer cells that become growth
signals for these cancer cells to have
uncontrolled growth there are pathways
within the cancer cells that drive
uncontrolled growth that we are not able
to stop and so the question is how do we
target this and we can target this by
giving an antibody against these
receptors and we can target this by also
giving innovators small molecules that
block these pathways and you say this is
great we know what targets cancer we
know how to approach it this is the best
way to treat to cancer the challenges
that cancer cells are smart they say
okay if you’re gonna block this receptor
if you’re gonna block this pathway I’m
going to circumvent it I’m gonna come up
with a different pathway and drop
resistance to your drug that you’re
offering
so we said alright we’re going to give
you multiple target pathway and abetters
then we start getting into toxicity then
we said okay what if we know
chemotherapy works we know what this
collateral damage that happens with
chemotherapy
what if we were to combine chemotherapy
with an antibody and a concept called
antibody drug conjugate what if we take
the chemos her boot right to the cancer
cell and use the antibody to direct this
chemotherapy within the cancer cell it
was shown to be helpful in lymphoma and
we showed it was helpful in breast
cancer the challenges that these targets
that we have in breast cancer for
instance there’s about 15 to 20% of our
patient
who are responsive to that kind of
concept but there’s many other patients
who do not respond to the targeted
therapies because we’re still not sure
what the target is
so targeted therapy is still part and
and clearly what we need to do for our
patients with cancer but then we started
to shift a little bit and we said what
if we use our own body’s immune system
so what happens is that we have immune
cells that recognize foreign cells could
be infection could be cancer cells and
they say you don’t look great you don’t
belong here you need to be removed from
air and they target those cells and the
cancer cells are able to drop in hiding
mechanism they say well I am one of you
don’t look at me keep moving on and they
hide away from our own immune system and
scientists started to discover this
hiding mechanism to see how our cancer
cells hiding from our active immune
cells t-cells are circulating around
looking for these foreign objects and
they found the reason why they found the
receptors and the proteins that make
these cancer cells hide away from the
immune system and then said why don’t we
attack these proteins and that’s exactly
what happened around ten years ago we
started to drop therapies called immune
therapies where suddenly the cancer
cells are much more visible and the
immune cells are much more likely to be
able to attract to these cancer cells
uncover them and target them and now in
melanoma in kidney cancer and lung
cancer in head and neck cancer we use
immune therapies for treatment of cancer
the challenges but still only about ten
percent of our cancer patients benefit
from immune therapy and some situations
we may give the drug but the immune
system doesn’t waken up so the
scientists are now looking at how do we
wake up the immune system and one of the
ideas was why don’t we take the t-cells
from the humans which are affected by
cancer engineered these t-cells to
recognise cancer cells and put and Riaan
fuse these t-cells back into these
patients with cancer
since were able to engineer a immune
system to recognize cancer these drugs
have just been approved as of this year
by FDA there’s still a challenge there’s
heterogeneity
there’s escape mechanisms and the
question is you know we may have 10 15
percent of our patients are benefitting
and this is driven by clinical trials
but that’s a small subset of patients
how do we move forward if you’re really
going to change cancer cure and that
road ahead needs us to take a look back
as to where we came from and this
started to change with the Human Genome
Project the Human Genome Project many of
you are aware looked at genome which is
really all this DNA that we have in our
cells nucleus and they said let’s
sequence all the DNA to know what we’re
all about so from the year in 1990 to
2003 there were about 2.7 billion
dollars spent to understand what is the
DNA I Inhumans it took 2.7 billion
dollars to be able to sequence the DNA
to understand what the human genome look
like in 2005 they said why don’t we do
the same for cancer so that we can
catalog these genetic mutations so we
can understand what’s driving cancer the
challenge was cost because we were
looking at millions and millions of
dollars but thankfully the sequencing
cost Ari to drop down it went from
hundreds of millions of dollars in 2008
it went to 10 million dollars and now
you can sequence your own human genome
for less than a thousand dollars but the
challenge is data if we take a look at
33 cancer subtypes that have been
sequenced so far that data equals 22.0
petabyte each petabyte is equal to about
$220,000 – and 20,000 DVDs that’s the
amount of storage that is needed for
understanding cancer so the question is
maybe we don’t need to sequence all the
human genome maybe we just need to look
for those mutations that we can do
something about something called
actionable mutations mutations where we
have a drug that we can give to our
patients mutations that we can actually
act upon
that’s the concept called next-gen
sequencing and that’s what’s been
applied to cancer care to be able to
understand that what if we didn’t have
to biopsy the tumor what if we just took
a blood test and recognized cancer cells
and sequence the DNA on those individual
cancer cells concept called liquid
biopsy that we are understanding and
delivering now for our patients but the
challenge is data so if you just take a
look at all the labs in the world which
are doing that the amount of data that
is needed in 2017 to look at those
cancer cells and this is just patients
are in clinical trials is one exabyte an
exabyte is million times a million times
a million bytes that’s how much data
would be needed just for us to to
collect the information the question
then is what do we do with all this
information and the real answer to that
is we need to have the right people on
the table when we making treatment
decision making so suddenly the decision
about what treatment we need to give to
our cancer patients is not just as
doctors as nurses and healthcare
providers we need computer scientists we
need mathematicians we need bar
informaticians to be there alongside us
to be able to take a look at this data
but that data just tells us about the
cancer it tells us about what’s
happening at the level of the tumor it
doesn’t tell us what else is happening
in those patients who did not go on
clinical trials if we have 17 million
patients who are diagnosed with cancer
what if we had electronic health record
data from all these hundreds of
thousands and millions of patients and
understand what happened to them when
they receive treatment so understand how
did they respond to the drugs to
understand their ethnicity their age the
core morbidities how what if we had that
data what if we asked our patients to
record their data something called
patient reported outcomes when they’re
at home what side effect they had what
symptom they had and what if we had a
way of looking at all the knowledge that
is coming in the medical literature and
integrating that with a patient of old
era that is a road ahead for us to be
able to look at the tumor biology to
look at the electron
like health records to look at patient
reported outcomes to be able to
integrate and assimilate the information
is coming in the medical literature then
to be able to integrate this information
inform our patients that this is the
treatment that you need to have so the
future of cancer is dependent on
advances that were made in treatment but
the future of cancer is going to be
dependent on data and the only way we
can outsmart cancer is byte by byte by
integrating and informing our patients
based on data thank you very much
[Applause]
[Music]
Please follow and like us: